Dedifferentiated umbilical metastases from low grade endometrioid endometrial adenocarcinoma complicated by super-obesity: A case report

por Odgers, Harrison, Anderson, Lyndal, Kok, Peey Sei, Farrell, Rhonda
Publicado 2023

A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clin...

por Mercieca-Bebber, Rebecca, Friedlander, Michael, Calvert, Melanie, Stockler, Martin, Kyte, Derek, Kok, Peey-Sei, King, Madeleine T.
Publicado 2017

Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

por Tjokrowidjaja, Angelina, Lord, Sarah J., John, Thomas, Lewis, Craig R., Kok, Peey‐Sei, Marschner, Ian C., Lee, Chee K.
Publicado 2022

Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-...

por Kok, Peey-Sei, Cho, Doah, Yoon, Won-Hee, Ritchie, Georgia, Marschner, Ian, Lord, Sally, Friedlander, Michael, Simes, John, Lee, Chee Khoon
Publicado 2020

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression

por Kok, Peey-Sei, Beale, Philip, O'Connell, Rachel L., Grant, Peter, Bonaventura, Tony, Scurry, James, Antill, Yoland, Goh, Jeffrey, Sjoquist, Katrin, DeFazio, Anna, Mapagu, Cristina, Amant, Frederic, Friedlander, Michael
Publicado 2019

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

por Antill, Yoland, Kok, Peey-Sei, Robledo, Kristy, Yip, Sonia, Cummins, Michelle, Smith, Deborah, Spurdle, Amanda, Barnes, Elizabeth, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally, Shannon, Catherine, Coward, Jermaine, Beale, Philip, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine, Andrews, John, Stockler, Martin R, Mileshkin, Linda
Publicado 2021

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial

por Kok, Peey Sei, Forde, Patrick M, Hughes, Brett, Sun, Zhuoxin, Brown, Chris, Ramalingam, Suresh, Cook, Alistair, Lesterhuis, Willem Joost, Yip, Sonia, O’Byrne, Ken, Pavlakis, Nick, Brahmer, Julie, Anagnostou, Valsamo, Ford, Kate, Fitzpatrick, Karen, Bricker, Alison, Cummins, Michelle M, Stockler, Martin, Nowak, Anna K
Publicado 2022

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)

por Smith, Deborah, Robledo, Kristy P., Yip, Sonia, Cummins, Michelle M., Kok, Peey-Sei, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally, Shannon, Catherine, Coward, Jermaine, Beale, Philip, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine, Spurdle, Amanda B., Andrews, John, Stockler, Martin R., Mileshkin, Linda, Antill, Yoland
Publicado 2022